Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics Limited has released its Appendix 4E Preliminary Final Report and 2025 Annual Report, highlighting its ongoing efforts in advancing FAK inhibitors. This development could enhance the company’s position in the pharmaceutical industry, particularly in the treatment of fibrotic cancers and chronic diseases, potentially impacting stakeholders positively.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 1,677,450
Technical Sentiment Signal: Sell
Current Market Cap: A$19.4M
For an in-depth examination of ATX stock, go to TipRanks’ Stock Analysis page.